A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf067 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Victor T G Lin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Mary Bird Perkins Cancer Center, Baton Rouge, LA 70809, United States. Hauptthemen laut MEDLINE: Precision Medicine, High-Throughput Nucleotide Sequencing, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Genentech, Inc.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Next-generation sequencing (NGS) testing in patients with metastatic non-small cell lung cancer (mNSCLC) identifies actionable driver oncogenes (ADO) and targeted treatment (TT). Potential inequities were evaluated in NGS testing and TT in patients with mNSCLC. Patients and methods This retrospective study used a nationwide electronic health record–derived deidentified database for patients ≥18 years diagnosed with mNSCLC between 4/2018 and 4/2024, ≥2 recorded visits, and follow-up ≥90 days post diagnosis. For TT, patients must have received NGS testing before first-line (1L) treatment and harbored ≥1 1L ADO.
Results
A total of 15 392 patients with mNSCLC were included: 66% with commercial insurance, 16% with Medicare, 12% with other, 4% with Medicaid, and 3% with other government insurance. Patients with commercial insurance had significantly higher odds of receiving NGS testing vs Medicare, Medicaid, or other insurance. While patient characteristics varied across insurances, the effect of insurance type on NGS testing did not differ by race/ethnicity, age, or socioeconomic status (SES). Site of care was a significant effect modifier, with increased odds of NGS testing for community vs academic settings for commercial, Medicare, and other insurance and decreased odds for Medicaid. When all patients received NGS testing, significantly lower odds of receiving TT occurred for patients with SES 2 vs SES 1 (lowest); higher odds occurred for Asian vs white patients.
Conclusion
Insurance is a key contributor to inequity in NGS testing. When all patients received NGS testing, equity was achieved in patients receiving TT, except those with lower SES, who potentially did not qualify for Medicaid.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mary Bird Perkins Cancer Center, Baton Rouge, LA 70809, United States.
- Genentech, Inc., South San Francisco, CA 94080, United States.
- OneOncology LLC, Nashville, TN, United States.
- Tennessee Oncology, Nashville, TN 37219, United States.
- Foundation Medicine, Inc., Boston, MA 02210, United States.
- West Cancer Center and Research Institute, Memphis, TN 38104, United States.
ORCID-Profile: Victor T G Lin
Förderung
- Genentech, Inc
Zitieren
APA
Lin, V. T. G., Ma, E., Jain, N., Xia, Z., Sheinson, D., Yu, E., Daniel, D., Huang, R. S. P., Vidal, G., Martin, R. L., Zuniga, R., & Stricker, T. (2025). A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment. The Oncologist. https://doi.org/10.1093/oncolo/oyaf067
Vancouver
Lin VTG, Ma E, Jain N, Xia Z, Sheinson D, Yu E, et al. A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment. The Oncologist. 2025. doi:10.1093/oncolo/oyaf067
BibTeX
@article{Lin2025,
author = {Lin, Victor T G and Ma, Esprit and Jain, Neha and Xia, Zhiyu and Sheinson, Danny and Yu, Elaine and Daniel, Davey and Huang, Richard S P and Vidal, Gregory and Martin, Richard Lewis and Zuniga, Richard and Stricker, Thomas},
title = {A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf067}
}
EUVIMED